Rituximab Therapy in Patients With Treatment Refractory Hypersenstivity Pneumonitis

"In Chronic hypersensitivity pneumonitis patients with no improvement in lung function (deterioration in their FVC% predicted more than or equal 5%) after a minimum of 6 months treatment including antigen avoidance and immunosuppressive therapy. Rituximab will be administered by an intravenous infusion.~* Two doses of Rituximab will be given, the first dose at day 0 and the second dose at day 15, 1 gram of Rituximab will be given in each dose.~* Patients will be given acetaminophen and antihistamine before each infusion.~* Rituximab will be diluted in an infusion bag of either 0.9% sodium chloride or 5% dextrose.~* No other drugs will be mixed with it, and patients will be closely monitored for any infusion reactions."